Results 81 to 90 of about 35,970 (259)

Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma.

Blood Advances, 2020
Despite unprecedented efficacy, 1 the use of axicabtagene ciloleucel (axi-cel) for the treatment of patients with relapsed or refractory large B-cell lymphoma (LBCL) remains associated with acute toxicity, such as grade $ 3 cytokine release syndrome (CRS)
P. Strati, Saira S. Ahmed, P. Kebriaei, L. Nastoupil, Catherine M. Claussen, G. Watson, S. Horowitz, A. R. Brown, Bryan Do, M. Rodriguez, R. Nair, E. Shpall, Michael R. Green, S. Neelapu, J. Westin   +14 more
semanticscholar   +1 more source

Treatment Experiences with Intravenous Immunoglobulins, Ixekizumab, Dupilumab, and Anakinra in Netherton Syndrome: A Case Series

Dermatology, 2022
Background: Netherton syndrome (NS) is a rare potential life-threatening disorder that causes severe defects to the skin barrier. No effective treatment options are available for patients with NS and current therapy is mostly supportive.
A. Ragamin, A. Nouwen, V. A. Dalm, M. V. van Mierlo, C. Lincke, S. Pasmans   +5 more
semanticscholar   +1 more source

Comparative efficacy and safety of anakinra and canakinumab in patients with VEXAS syndrome – an international multicenter study

Arthritis &Rheumatology, Accepted Article.
Objectives The aim of this study was to compare differences in clinical response, drug survival, and adverse event rates between anakinra and canakinumab in VEXAS syndrome. Methods This multicenter international study includes VEXAS patients from France, Israel, and Italy treated with IL1 inhibition (IL1i).
Tali Eviatar, Dafne Capelusnik, Corrado Campochiaro, Valentin Lacombe, Vincent Jachiet, Michael Zisapel, Iftach Sagy, Oshrat E. Tayer‐Shifman, David Ozeri, Shaye Kivity, Alessandro Tomelleri, Benjamin Terrier, Hagit Peleg, Thibault Comont, Karim Sacre, Pascal Woaye‐Hune, Laurent Arnaud, Estibaliz Lazaro, Vincent Grobost, Francois Lifermann, Maxime Samson, Samuel Ardois, Alice Garnier, Alexandre Maria, Alain Cantagrel, Aurore Meyer, Jean‐David Bouaziz, Mael Heiblig, Lorenzo Dagna, Elisa Diral, Olivier Kosmider, Ori Elkayam, Jérôme Hadjadj, Sophie Georgin‐Lavialle, Olivier Fain, Arsene Mekinian   +35 more
wiley   +1 more source

Interleukin-1 blockade with Anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials.

European Heart Journal - Cardiovascular Pharmacotherapy, 2021
AIMS ST segment elevation myocardial infarction (STEMI) is associated with an intense acute inflammatory response and an increased risk of death and heart failure (HF). In this study we sought to evaluate the effect of anakinra, a recombinant interleukin-
A. Abbate, G. Wohlford, M. D. Del Buono, J. Chiabrando, R. Markley, J. Turlington, D. Kadariya, C. Trankle, G. Biondi‐Zoccai, M. Lipinski, B. V. Van Tassell   +10 more
semanticscholar   +1 more source

Effect of time to start of biologic therapy on treatment response in childhood arthritis: Results from the UCAN CAN‐DU study

Arthritis &Rheumatology, Accepted Article.
Objective To estimate the effect of time from symptom onset to start of biologic treatment on achieving inactive arthritis within six months in a cohort of juvenile idiopathic arthritis (JIA) patients. Methods The international UCAN CAN‐DU study prospectively enrolls JIA patients across Canada and the Netherlands.
Jelleke B. de Jonge, Sytze de Roock, Dieneke Schonenberg‐Meinema, J. Merlijn van den Berg, Deborah A. Marshall, Sebastiaan J. Vastert, Rae S.M. Yeung, Joost F. Swart, Susanne M. Benseler, The UCAN CAN‐DU and UCAN CURE consortia, Adam Huber, Alan Rosenberg, Alexander Mosoiu, Alisa Rachlis, Amy Xu, Andrea Human, Annet van Royen‐Kerkhof, Arthur Cheng, Berent Prakken, Bianca Lang, Brenleigh Jebb, Brian Feldman, Bruno Pereira, Chelsea DeCoste, Ciarán Duffy, Claire LeBlanc, Clare Hutchinson, Daniah Basodan, Danielle Brinkman, David Cabral, Dax G. Rumsey, Deborah Levy, Dilan Dissanayake, Elizabeth Legger, Elizabeth Stringer, Elizaveta Limenis, Ellen Schatorje, Elodie Boudes, Erika Van Nieuwenhove, Erkan Demirkaya, Esther Hoppenreijs, Evelyn Rozenblyum, Gaëlle Chédeville, Gillian Currie, Giske Biesbroek, Gordon Soon, Harper Cheng, Heinrike Schmeling, Herman Tam, Hon Yan Ng, Jaime Guzman, Jeanine McColl, Jennifer Ji Young Lee, Jonathan Park, Joseph Cafazzo, Kate Neufeld, Kim Morishita, Kristin Houghton, Liane Heale, Lillian Lim, Lily Lim, Lori Tucker, Lynn Spiegel, Maarten IJzerman, Marc Jansen, Mariken Gruppen, Marinka Twilt, Marleen Verkaaik, Mehul Jariwala, Mercedes Chan, Michelle Batthish, Michelle Kip, Muhammed Dhalla, Nadia Luca, Nickolas Blanchette, Nico Wulffraat, Nicole Johnson, Paivi Miettunen, Paul Dancey, Petra Hissink Muller, Philomine van Pelt, Piya Lahiry, Ravneet Sran, Rayfel Schneider, Rebeka Stevenson, Regina de Geus, Roberta Berard, Roman Jurencak, Ronald Laxer, Rosie Scuccimarri, Ross Petty, Ruud Verstegen, Sarah Campillo, Shirley Tse, Suzanne Ramsey, Sylvia Kamphuis, Tala El Tal, Tania Cellucci, Tara McGrath, Tommy Gerschman, Trang Duong, Tristan Kerr, Wineke Armbrust   +102 more
wiley   +1 more source

Anti-IL1 in patients with low penetrance mutations for autoinflammatory diseases: tuscany and sicilian case series from paediatric to adult age [PDF]

, 2017
Patients with low penetrance mutations for Autoinflammatory syndromes (AID) can have severe clinical manifestations, which require to be treated with biological drugs anti-IL-1.
Giovanni Corsello, Luca Cantarini, Maria Cristina Maggio, Rolando Cimaz, Umberto Corpora   +4 more
core  

Neonatal treatment of CINCA syndrome. [PDF]

, 2014
: Chronic Infantile Neurological Cutaneous Articular (CINCA) syndrome, also called Neonatal Onset Multisystem Inflammatory Disease (NOMID) is a chronic disease with early onset affecting mainly the central nervous system, bones and joints and may lead to
Berthet, G., Hofer, M., Mivelaz, Y., Paccaud, Y., Roth-Kleiner, M., Vaudaux, B., Von Scheven-Gête, A.   +6 more
core   +3 more sources

Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID‐19 patients: A systematic review and meta‐analysis

Reviews in Medical Virology, 2021
As the pandemic progresses, the pathophysiology of coronavirus disease 2019 (COVID‐19) is becoming clearer and the potential for immunotherapy is increasing.
Jingwen Peng, Mei-hua Fu, Huan Mei, Hailin Zheng, Guanzhao Liang, Xiaodong She, Qiong Wang, Weida Liu   +7 more
semanticscholar   +1 more source

A scoping review of disease‐modifying antirheumatic drug nonadherence in rheumatoid arthritis: Measurement, prevalence and implications for clinical practice

British Journal of Clinical Pharmacology, EarlyView.
Aims Adherence to disease‐modifying antirheumatic drugs (DMARDs) has been associated with improved treatment outcomes, but how adherence is reported ranges between studies. We therefore aimed to determine how nonadherence to DMARDs used to treat rheumatoid arthritis (RA) has been measured and to report the nonadherence rate with each measure identified.
Lauren Fraser, Nagham Ailabouni, Lisa Kalisch Ellett, Jiun Ming Tan, Anthea Freeman, Susanna M. Proudman, Emily Reeve, Michael D. Wiese   +7 more
wiley   +1 more source

Intravenous high-dose anakinra drops venous thrombosis and acute coronary syndrome in severe and critical COVID-19 patients: a propensity score matched study

Scientific Reports
In our study, we aimed to evaluate the effect of high-dose intravenous anakinra treatment on the development of thrombotic events in severe and critical COVID-19 patients. This retrospective observational study was conducted at a tertiary referral center
Ramazan Çakmak, Servet Yüce, Mustafa Ay, Muhammed Hamdi Uyar, Muhammed İkbal Kılıç, Murat Bektaş   +5 more
doaj   +1 more source